Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 58Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 23Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Recurrence 16Lymphoma, Non-Hodgkin 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 10Neoplasms, Plasma Cell 9Waldenstrom Macroglobulinemia 6Hodgkin Disease 6Neoplasms 5Leukemia, Myeloid, Acute 5Burkitt Lymphoma 5Lymphoma, T-Cell 4Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Anaplastic 3Leukemia 3Hematologic Neoplasms 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

Temozolomide 3Filgrastim 2Drug Therapy 2talazoparib 1sargramostim 1pembrolizumab 1oblimersen 1irinotecan sucrosofate 1etoposide phosphate 1entrectinib 1atezolizumab 1X-Rays 1Vincristine 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Proteasome Inhibitors 1Platinum 1Phantoms, Imaging 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Monatide (IMS 3015) 1Microarray Analysis 1Lenalidomide 1Isotretinoin 1Irinotecan 1Immunomodulating Agents 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Wilms Tumor × Lenalidomide × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡